WO2003029469A1 - Nouvelles proteines contenant de la selenocysteine - Google Patents
Nouvelles proteines contenant de la selenocysteine Download PDFInfo
- Publication number
- WO2003029469A1 WO2003029469A1 PCT/JP2002/009313 JP0209313W WO03029469A1 WO 2003029469 A1 WO2003029469 A1 WO 2003029469A1 JP 0209313 W JP0209313 W JP 0209313W WO 03029469 A1 WO03029469 A1 WO 03029469A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- selenocystein
- novel
- gene
- containing proteins
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003532683A JP4199662B2 (ja) | 2001-09-13 | 2002-09-12 | 新規なセレノシステイン含有タンパク質 |
US10/489,716 US20060051851A1 (en) | 2001-09-13 | 2002-09-12 | Novel selenocysteine-containing protein |
EP02767954A EP1437410A4 (de) | 2001-09-13 | 2002-09-12 | Neue selenocystein enthaltende proteine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-278749 | 2001-09-13 | ||
JP2001278749 | 2001-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003029469A1 true WO2003029469A1 (fr) | 2003-04-10 |
Family
ID=19103066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/009313 WO2003029469A1 (fr) | 2001-09-13 | 2002-09-12 | Nouvelles proteines contenant de la selenocysteine |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060051851A1 (de) |
EP (1) | EP1437410A4 (de) |
JP (1) | JP4199662B2 (de) |
WO (1) | WO2003029469A1 (de) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004050114A1 (ja) * | 2002-11-29 | 2004-06-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 新規な神経伝達機能異常疾患改善剤 |
US9173960B2 (en) | 2011-11-04 | 2015-11-03 | Novartis Ag | Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs |
US9290573B2 (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
US9428583B2 (en) | 2010-05-06 | 2016-08-30 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
JP2017521417A (ja) * | 2014-07-04 | 2017-08-03 | 長弘生物科技股▲ふん▼有限公司 | フタリド化合物の使用 |
US9889117B2 (en) | 2014-07-02 | 2018-02-13 | Everfront Biotech Inc. | Method for treating and/or delaying the degeneration of Purkinje cells |
JP2019520083A (ja) * | 2016-07-11 | 2019-07-18 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | セレノシステインを含む組換えポリペプチド及びその製造方法 |
WO2022025184A1 (ja) | 2020-07-29 | 2022-02-03 | 中外製薬株式会社 | 非放射性物質で標識した薬剤の薬物動態を測定する方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236936B2 (en) * | 2005-06-21 | 2012-08-07 | Ohio State University | Production of recombinant selenoprotein mutants with enhanced catalytic activity |
-
2002
- 2002-09-12 JP JP2003532683A patent/JP4199662B2/ja not_active Expired - Fee Related
- 2002-09-12 EP EP02767954A patent/EP1437410A4/de not_active Withdrawn
- 2002-09-12 WO PCT/JP2002/009313 patent/WO2003029469A1/ja not_active Application Discontinuation
- 2002-09-12 US US10/489,716 patent/US20060051851A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
DEAGEN J.T. ET AL.: "Chemical forms of selenium in selenium containing proteins from human plasma", J. INORG. BIOCHEM., vol. 41, no. 4, 1991, pages 261 - 268, XP002957615 * |
HAZEBROUCK S. ET AL.: "Substituting selenocysteine for catalytic cysteine 41 enhances enzymatic activity of plant phospholipid hydroperoxide glutathione peroxidase expressed in escherichia coli", J. BIOL. CHEM., vol. 275, no. 37, 2000, pages 28715 - 28721, XP002957614 * |
HURST R. ET AL.: "Phospholipid hydroperoxide cysteine peroxidase activity of human serum albumin", BIOCHEM. J., vol. 338, 1999, pages 723 - 728, XP002957613 * |
See also references of EP1437410A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004050114A1 (ja) * | 2002-11-29 | 2004-06-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 新規な神経伝達機能異常疾患改善剤 |
US9290573B2 (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
US9428583B2 (en) | 2010-05-06 | 2016-08-30 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
US9173960B2 (en) | 2011-11-04 | 2015-11-03 | Novartis Ag | Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs |
USRE47860E1 (en) | 2011-11-04 | 2020-02-18 | Novartis Ag | Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs |
US9889117B2 (en) | 2014-07-02 | 2018-02-13 | Everfront Biotech Inc. | Method for treating and/or delaying the degeneration of Purkinje cells |
JP2017521417A (ja) * | 2014-07-04 | 2017-08-03 | 長弘生物科技股▲ふん▼有限公司 | フタリド化合物の使用 |
JP2019520083A (ja) * | 2016-07-11 | 2019-07-18 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | セレノシステインを含む組換えポリペプチド及びその製造方法 |
US11155804B2 (en) | 2016-07-11 | 2021-10-26 | Board Of Regents, The University Of Texas System | Recombinant polypeptides comprising selenocysteine and method for producing the same |
JP7269648B2 (ja) | 2016-07-11 | 2023-05-09 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | セレノシステインを含む組換えポリペプチド及びその製造方法 |
WO2022025184A1 (ja) | 2020-07-29 | 2022-02-03 | 中外製薬株式会社 | 非放射性物質で標識した薬剤の薬物動態を測定する方法 |
Also Published As
Publication number | Publication date |
---|---|
US20060051851A1 (en) | 2006-03-09 |
EP1437410A1 (de) | 2004-07-14 |
EP1437410A4 (de) | 2005-01-26 |
JP4199662B2 (ja) | 2008-12-17 |
JPWO2003029469A1 (ja) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003104270A3 (en) | GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES | |
AU2002233643A1 (en) | Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases | |
WO2002022821A3 (en) | Antimicrobial peptides and methods of use | |
WO2003048324A3 (en) | Antisense modulation of phospholipid scramblase 3 expression | |
WO2003053423A3 (en) | Inhibition or prevention of infection by bacteria with epa, dha or analogs | |
WO2003029469A1 (fr) | Nouvelles proteines contenant de la selenocysteine | |
WO2005004814A3 (en) | Sirt1 and genetic disorders | |
WO2001036465A3 (en) | Human zven proteins | |
AU6090799A (en) | Transgenic c. elegans as a model organism for research into alzheimer's disease | |
WO2004024072A3 (en) | Novel compositions and methods for the treatment of immune related diseases | |
AU2003285346A1 (en) | Regulatory elements in the 5' region of the vr1 gene | |
AU2001245319A1 (en) | Methods of treating diseases with activated protein c | |
WO2003055440A8 (en) | Compositions and methods for the treatement of immune related diseases | |
WO2000068364A3 (en) | Mutations in nucleic acid molecules encoding 11-cis retinol dehydrogenase, the mutated proteins, and uses thereof | |
WO2001040465A3 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2003027229A3 (en) | Antisense modulation of rip2 expression | |
WO2003040161A3 (en) | Antisense modulation of activating transcription factor 3 expression | |
WO2004053117A3 (en) | Serine protease | |
AU2002306860A1 (en) | Isolated human nadph oxidase, nucleic acid molecules encoding said proteins, and uses thereof | |
WO2001092524A3 (en) | Myosin-like gene expressed in human heart and muscle | |
EP1293570A3 (de) | Verwendung des Aprataxin Gens zur Diagnose und Behandlung der früheinsetzenden Hinterstrangataxie (EAOH - early-onset spinocerebellar ataxia) | |
AU2001292326A1 (en) | Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like | |
AU2001289886A1 (en) | Regulation of human adam-ts 1 precursor-like protein | |
WO2002097108A3 (en) | Antisense modulation of dual specific phosphatase 5 expression | |
WO2004004649A3 (en) | Compositions and methods for the treatment of immune related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003532683 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006051851 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10489716 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002767954 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002767954 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10489716 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002767954 Country of ref document: EP |